Phase I trial of single-agent recombinant human anti-vascular endothelial growth factor (GB222) followed a combination therapy of GB222 and temozolomide in patients with recurrent WHO grade III and IV glioma
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.